Skip to main content
PRFX
NASDAQ Life Sciences

PainReform's OcuRing™-K Platform Shows Favorable Safety in Phase I & Preclinical Studies

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.83
Mkt Cap
$3.326M
52W Low
$0.611
52W High
$6.65
52W Position info
36% above low
Off High info
88% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PRFX sits 36% above its 52-week low of $0.611.

Summary

PainReform announced positive safety results for its OcuRing™-K drug delivery platform from preclinical and Phase I studies, paving the way for further clinical development and IND submission.


Key Events · Product Development and Regulatory · PRFX

  • Favorable Safety Profile Demonstrated

    The OcuRing™-K delivery platform showed a favorable safety profile in both preclinical rabbit studies and a Phase I human clinical study.

  • No Treatment-Related Adverse Events

    The Phase I study observed no treatment-emergent adverse events related to the study drug, with all reported events consistent with cataract surgery.

  • Advancement Towards IND Submission

    The consistent safety data supports the continued advancement of the OcuRing™-K platform towards an Investigational New Drug (IND) submission for further clinical evaluation.

  • Sustained-Release Ocular Delivery

    OcuRing™-K is an intraocular drug delivery system designed for targeted, sustained release of ophthalmic therapeutics, aiming to minimize local irritation and systemic exposure.


Analysis · PRFX · Life Sciences

This 6-K reports positive safety data from preclinical and Phase I clinical studies for PainReform's OcuRing™-K drug delivery platform. The favorable safety profile, with no treatment-related adverse events, is a critical de-risking step for the clinical-stage company. This milestone supports the platform's advancement towards an Investigational New Drug (IND) submission, which is essential for further clinical evaluation in the United States. For a micro-cap pharmaceutical company, successful early-stage clinical data is a significant positive development that can enhance investor confidence and future funding prospects.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRFX was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.61 to $6.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRFX - Latest Insights

PRFX
Nov 13, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.7834
Real-time Price: $0.740 info
Change: -$0.0434 (-6%) info
Market Cap: $2.381M info
PRFX
Nov 12, 2026, 4:31 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.7354
Real-time Price: $0.740 info
Change: +$0.0046 (+0.63%) info
Market Cap: $2.381M info
PRFX
Nov 12, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.786
Real-time Price: $0.740 info
Change: -$0.046 (-6%) info
Market Cap: $2.381M info
PRFX
Nov 05, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.7588
Real-time Price: $0.740 info
Change: -$0.0188 (-2%) info
Market Cap: $2.381M info
PRFX
Nov 03, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.7705
Real-time Price: $0.740 info
Change: -$0.0305 (-4%) info
Market Cap: $2.381M info